Intravitreal quantum dots for retinitis pigmentosa: a first-in-human safety study

Area of Science:

• Ophthalmology
• Biomedical Engineering
• Materials Science

Background:

• Electrical stimulation shows therapeutic potential for retinitis pigmentosa (RP).
• Quantum dots (QDs) convert light to electrical stimuli, suggesting a novel therapeutic approach for RP.
• RP is a group of inherited eye diseases that cause progressive vision loss.

Purpose of the Study:

• To evaluate the safety and potential efficacy of intravitreal quantum dots (QDs) in patients with retinitis pigmentosa (RP).
• To assess the therapeutic benefit of QD-based electrical stimulation for vision restoration in RP.

Main Methods:

• An open-label, fellow-eye-controlled, first-in-human safety study.
• Intravitreal injections of cadmium/selenium 655 Alt QDs were administered to adult patients with end-stage or severe RP.
• Visual acuity was monitored to assess potential vision improvement.

Main Results:

• No adverse events were attributed to the intravitreal QD injections.
• In patients with severe RP, a mean best-corrected visual acuity improvement from 6/398 to 6/177 was observed.
• No significant change in visual acuity was noted in patients with end-stage RP.

Conclusions:

• Intravitreal administration of QDs is safe for patients diagnosed with RP.
• QD treatment demonstrated potential vision benefits in patients with severe RP.
• Further clinical studies are warranted to validate these promising findings.